Late-onset vitamin K deficiency presenting as haemorrhagic shock and severe multi-system organ failure

被引:0
|
作者
Azar, Justin M. [1 ,2 ]
Lambert, Richard [1 ,2 ]
Maffei, Frank Anthony [1 ,2 ]
Thomas, Tessy A. [1 ,2 ]
机构
[1] Janet Weis Childrens Hosp, Danville, PA 17822 USA
[2] Geisinger Commonwealth Sch Med, Pediat, Scranton, PA 18509 USA
关键词
Preventative pediatrics; Neonatal and paediatric intensive care; Routine care of the full-time infant; Infant health; Haematology (incl blood transfusion); INTRACRANIAL HEMORRHAGE; THYMIC HEMORRHAGE; INFANTS; DISEASE;
D O I
10.1136/bcr-2024-261126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vitamin K is an essential dietary cofactor required for the synthesis of active forms of vitamin K-dependent procoagulant proteins. Vitamin K deficiency, particularly late-onset deficiency occurring between 1 week and 6 months of age, can cause a life-threatening bleeding disorder. An exclusively breastfed, full-term, 6-week-old infant male presented with severe haemorrhagic shock and multi-system organ failure related to caregiver refusal of intramuscular vitamin K after birth. Coagulation studies were normalised within 8 hours of intramuscular vitamin K administration. An increasing number of caregivers are refusing intramuscular vitamin K which has led to a rise in the incidence of vitamin K deficiency bleeding. Health policy organisations around the world emphasise the benefits of intramuscular vitamin K and risks of refusal, particularly in exclusively breastfed infants who are at higher risk due to low vitamin K levels in breast milk. This case highlights the multi-system severity of this life-threatening yet preventable disorder.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 26 条
  • [21] Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis
    Tsukasa Osaki
    Masayoshi Souri
    Young-seok Song
    Naohiro Izumi
    Ruby Law
    Akitada Ichinose
    Journal of Thrombosis and Thrombolysis, 2016, 42 : 218 - 224
  • [22] Multi-institutional emergency use of defibrotide (DF) in 75 pts post SCT with severe VOD and multi-system organ failure (MOF): Response without significant toxicity in a high risk population.
    Richardson, PG
    Murakami, C
    Warren, DL
    Jin, Z
    Neuberg, D
    Elias, AD
    Antin, J
    Soiffer, R
    Bearman, SI
    Vredenburgh, J
    Vogelsang, G
    Hoppensteadt, D
    Fareed, J
    Iacobelli, M
    McDonald, GB
    Guinan, EC
    BLOOD, 2000, 96 (11) : 585A - +
  • [23] Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT).
    Richardson, PG
    Soiffer, R
    Antin, JH
    Vredenburgh, J
    Kurtzberg, J
    Martin, PL
    Hockenbery, D
    Steinbach, G
    Murray, K
    Vogelsang, G
    Chen, A
    Warren, DL
    Momtaz, P
    Wei, LJ
    Jin, Z
    Rifai, N
    Bradwin, G
    Iacobelli, M
    McDonald, GB
    Guinan, EC
    BLOOD, 2002, 100 (11) : 112A - 112A
  • [24] Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study.
    Richardson, P
    Soiffer, RJ
    Antin, JH
    Jin, Z
    Vredenburgh, JJ
    Kurtzberg, J
    Martin, PL
    Hockenbery, D
    Steinbach, G
    Murray, KF
    Vogelsang, GB
    Chen, A
    Krishnan, A
    Prasad, VK
    Warren, DL
    Momtaz, P
    Batchelder, A
    Wei, LJ
    Rifai, N
    Bradwin, G
    Iacobelli, M
    McDonald, GB
    Guinan, EC
    BLOOD, 2003, 102 (11) : 193A - 193A
  • [25] Defibrotide (DF) for the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post SCT: Final results of a phase II, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasound findings
    Richardson, PG
    Soiffer, RJ
    Antin, JH
    Voss, SD
    Jin, Z
    Kurtzberg, J
    Martin, PL
    Hockenbery, D
    Murray, KF
    Vogelsang, GB
    Chen, A
    Krishnan, A
    Kernan, NA
    Avigan, D
    Spitzer, TR
    Iannone, R
    Giralt, S
    Warren, D
    Momtaz, P
    Bradwin, G
    Iacobelli, M
    McDonald, GB
    Guinan, EC
    BLOOD, 2004, 104 (11) : 103A - 104A
  • [26] Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population.
    Richardson, PG
    Warren, DL
    Momtaz, P
    Soiffer, R
    Antin, JH
    Spitzer, T
    Avigan, D
    Wei, LJ
    Jin, Z
    Rifai, N
    Bradwin, G
    Vredenburgh, J
    Kurtzberg, J
    Martin, PL
    Vogelsang, G
    Arai, S
    Chen, A
    McDonald, GB
    Murray, K
    Iacobelli, M
    Guinan, EC
    BLOOD, 2001, 98 (11) : 853A - 853A